These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 21742831

  • 1. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.
    Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, Coombs GW, Johnson PD, Howden BP.
    J Infect Dis; 2011 Aug 01; 204(3):340-7. PubMed ID: 21742831
    [Abstract] [Full Text] [Related]

  • 2. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J.
    Clin Infect Dis; 2008 Jan 15; 46(2):193-200. PubMed ID: 18171250
    [Abstract] [Full Text] [Related]

  • 3. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.
    Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, Johnson PD, Howden BP.
    Clin Microbiol Infect; 2013 Dec 15; 19(12):1163-8. PubMed ID: 23441652
    [Abstract] [Full Text] [Related]

  • 4. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia?
    de Sanctis JT, Swami A, Sawarynski K, Gerasymchuk L, Powell K, Robinson-Dunn B, Carpenter CF, Sims MD.
    Diagn Mol Pathol; 2011 Sep 15; 20(3):184-8. PubMed ID: 21817905
    [Abstract] [Full Text] [Related]

  • 5. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
    Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A.
    Arch Intern Med; 2006 Oct 23; 166(19):2138-44. PubMed ID: 17060545
    [Abstract] [Full Text] [Related]

  • 6. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R, Davis SL, Levine DP, Rybak MJ.
    Clin Infect Dis; 2011 Apr 15; 52(8):975-81. PubMed ID: 21460309
    [Abstract] [Full Text] [Related]

  • 7. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC.
    J Antimicrob Chemother; 2011 Oct 15; 66(10):2386-92. PubMed ID: 21775337
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
    Brown J, Brown KA, Forrest A.
    Clin Ther; 2011 Oct 15; 33(10):1475-82. PubMed ID: 21925733
    [Abstract] [Full Text] [Related]

  • 11. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
    Ahmad NM, Rojtman AD.
    Ann Pharmacother; 2010 May 15; 44(5):918-21. PubMed ID: 20354160
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.
    Baxi SM, Clemenzi-Allen A, Gahbauer A, Deck D, Imp B, Vittinghoff E, Chambers HF, Doernberg S.
    Antimicrob Agents Chemother; 2016 Sep 15; 60(9):5276-84. PubMed ID: 27324762
    [Abstract] [Full Text] [Related]

  • 14. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
    Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ.
    Clin Infect Dis; 2013 Jun 15; 56(11):1562-9. PubMed ID: 23449272
    [Abstract] [Full Text] [Related]

  • 15. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM, Goff DA, Brown J, Khadem TM, Bauer KA.
    Clin Ther; 2013 Jun 15; 35(6):772-9. PubMed ID: 23795575
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections.
    Kopp BJ, Nix DE, Armstrong EP.
    Ann Pharmacother; 2004 Sep 15; 38(9):1377-82. PubMed ID: 15266044
    [Abstract] [Full Text] [Related]

  • 20. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients.
    Rojas L, Bunsow E, Muñoz P, Cercenado E, Rodríguez-Créixems M, Bouza E.
    J Antimicrob Chemother; 2012 Jul 15; 67(7):1760-8. PubMed ID: 22556382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.